Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/65865
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Novo, Isabel | por |
dc.contributor.author | Campos, Bárbara | por |
dc.contributor.author | Pinto-Ribeiro, Filipa | por |
dc.contributor.author | Martins, Sandra | por |
dc.date.accessioned | 2020-07-07T13:56:12Z | - |
dc.date.available | 2020-07-07T13:56:12Z | - |
dc.date.issued | 2020-04-18 | - |
dc.identifier.citation | Novo, I.; Campos, B.; Pinto-Ribeiro, F.; Martins, S.F. Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review. Gastrointest. Disord. 2020, 2, 71-85. | por |
dc.identifier.uri | https://hdl.handle.net/1822/65865 | - |
dc.description.abstract | Background: the presence of liver metastasis in colorectal cancer (CRC) remains one of the most significant prognostic factors. Objective: systematically review the results of studies evaluating the benefit of adding bevacizumab to a normal chemotherapy regime in the survival of patients with colorectal-cancer liver metastasis (CRLM). Search methods: Pubmed and Google Scholar databases were searched for eligible articles (from inception up to the 2 April 2019). Inclusion criteria: studies including patients with CRLM receiving anti-vascular endothelial growth factor (VEGF; bevacizumab) as treatment, overall survival as an outcome; regarding language restrictions, only articles in English were accepted. Main results: Eleven studies met the inclusion criteria. In 73% of these cases, chemotherapy with bevacizumab was an effective treatment modality for treating CRLM, and its administration significantly extended both overall survival (OS) and/or progression-free survival (PFS). Nevertheless, three articles showed no influence on survival rates of bevacizumab-associated chemotherapy. Author conclusions: It is necessary to standardize methodologies that aim to evaluate the impact of bevacizumab administration on the survival of patients with CRLM. Furthermore, follow-up time and the cause of a patient’s death should be recorded, specified, and cleared in order to better calculate the survival rate and provide a comparison between the produced literature. | por |
dc.description.sponsorship | This research received no external funding. | por |
dc.language.iso | eng | por |
dc.publisher | Multidisciplinary Digital Publishing Institute | por |
dc.rights | openAccess | por |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | por |
dc.subject | anti-VEGF | por |
dc.subject | colorectal cancer | por |
dc.subject | hepatic metastasis | por |
dc.subject | survival | por |
dc.title | Coadjuvant anti-VEGF A therapy improves survival in patients with colorectal cancer with liver metastasis: a systematic review | por |
dc.type | article | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.mdpi.com/2624-5647/2/2/7 | por |
oaire.citationIssue | 2 | por |
oaire.citationVolume | 2 | por |
dc.date.updated | 2020-07-01T06:44:08Z | - |
dc.identifier.eissn | 2624-5647 | - |
dc.identifier.doi | 10.3390/gidisord2020007 | por |
dc.subject.fos | Ciências Médicas::Ciências da Saúde | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Gastrointestinal Disorders | por |
oaire.version | VoR | por |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
gastrointestdisord-02-00007.pdf | 1,01 MB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons